Incorporation of novel 1-alkylcarbonyloxymethyl prodrugs of 5-fluorouracil into poly(lactide-co-glycolide) nanoparticles

International Journal of Pharmaceutics

Volumn 348, Issue 1-2, 2008, Pages 115-124

  McCarron, P A ^a   Hall, M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Alkylcarbonyloxymethyl; Fluorouracil; Nanoparticle; Poly(lactide co glycolide); Prodrug

Indexed keywords

DRUG CARRIER; FLUOROURACIL; NANOPARTICLE; POLYGLACTIN;

ARTICLE; DRUG FORMULARY; DRUG RELEASE; HYDROPHILICITY; LIPOPHILICITY; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PRECIPITATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; STEADY STATE;

DRUG STABILITY; ELECTROSTATICS; FLUOROURACIL; HYDROPHOBICITY; IMMUNOSUPPRESSIVE AGENTS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; POLYGLACTIN 910; PRODRUGS; SODIUM HYDROXIDE; SOLUBILITY; SURFACE PROPERTIES; TEMPERATURE;

EID: 37249015356     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.07.014     Document Type: Article

References (38)

1. Barichello J.M., Morishita M., Takayama K., and Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev. Ind. Pharm. 25 (1999) 471-476
2. Beall H.D., and Sloan K.B. Transdermal delivery of 5-fluorouracil (5-fu) by 1-alkylcarbonyl-5-fu prodrugs. Int. J. Pharm. 129 (1996) 203-210
3. Beall H., Prankerd R., and Sloan K. Transdermal delivery of 5-fluorouracil (5-fu) through hairless mouse skin by 1-alkyloxycarbonyl-5-fu prodrugs: physicochemical characterization of prodrugs and correlations with transdermal delivery. Int. J. Pharm. 111 (1994) 223-233
4. Bonina F.P., Puglia C., Barbuzzi T., de Caprariis P., Palagiano F., Rimoli M.G., and Saija A. In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur. J. Pharm. Sci. 14 (2001) 123-134
5. Brigger I., Dubernet C., and Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54 (2002) 631-651
6. Bundgaard H., Mork N., and Hoelgaard A. Enhanced delivery of nalidixic acid through human skin via acyloxymethyl ester prodrugs. Int. J. Pharm. 55 (1989) 91-97
7. Buur A., and Bundgaard H. Prodrugs of 5-fluorouracil I. Hydrolysis kinetics and physicochemical properties of various n-acyl derivatives of 5-fluorouracil. Int. J. Pharm. 21 (1984) 349-364
8. Buur A., Bundgaard H., and Falch E. Prodrugs of 5-fluorouracil. IV. Hydrolysis kinetics, bioactivation and physicochemical properties of various n-acyloxymethyl derivatives of 5-fluorouracil. Int. J. Pharm. 24 (1985) 43-60
9. Buur A., Bundgaard H., and Falch E. Prodrugs of 5-fluorouracil VII. Hydrolysis kinetics and physicochemical properties of n-ethoxy- and n-phenoxycarbonyloxymethyl derivatives of 5-fluorouracil. Acta Pharm. Suec. 23 (1986) 205-216
10. Chan S.Y., and Li Wan Po A. Prodrugs for dermal delivery. Int. J. Pharm. 55 (1989) 1-16
11. Chari R.V.J. Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv. Drug Deliv. Rev. 31 (1998) 89-104
12. Choi H.K., and Angello J.T. Mathematical analysis and optimization of a flow-through diffusion cell system. Pharm. Res. 11 (1994) 595-599
13. Chorny M., Fishbein I., Danenberg H.D., and Golomb G. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J. Control. Release 83 (2002) 389-400
14. Cordoba-Diaz M., Nova M., Elorza B., Cordoba-Diaz D., Chantres J.R., and Cordoba-Borrego M. Validation protocol of an automated in-line flow-through diffusion equipment for in vitro permeation studies. J. Control. Release 69 (2000) 357-367
15. Denny W.A. Prodrug strategies in cancer therapy. Eur. J. Med. Chem. 36 (2001) 577-595
16. Dubois V., Dasnois L., Lebtahi K., Collot F., Heylen N., Havaux N., Fernandez A.-M., Lobl T.J., Oliyai C., and Nieder A. Cpi-0004na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity. Cancer Res. 62 (2002) 2327-2331
17. Fonseca C., Simoes S., and Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control. Release 83 (2002) 273-286
18. Govender T., Stolnik S., Garnett M.C., Illum L., and Davis S.S. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J. Control. Release 57 (1999) 171-185
19. Grem J.L. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest. New Drugs 18 (2000) 299-313
20. Heiati H., Tawashi R., Shivers R.R., and Phillips N.C. Solid lipid nanoparticles as drug carriers. 1. Incorporation and retention of the lipophilic prodrug 3′-azido-3′-deoxythymidine palmitate. Int. J. Pharm. 146 (1997) 123-131
21. Hodoshima N., Udagawa C., Ando T., Fukuyasu H., Watanabe H., and Nakabayashi S. Lipid nanoparticles for delivering antitumor drugs. Int. J. Pharm. 146 (1997) 81-92
22. Johansen M., Mollgaard B., Wotton P.K., Larsen C., and Hoelgaard A. In vitro evaluation of dermal prodrug delivery-transport and bioconversion of a series of aliphatic esters of metronidazole. Int. J. Pharm. 32 (1986) 199-206
23. Kerr D., Roberts W., Tebbett I., and Sloan K.B. 7-Alkylcarbonyloxymethyl prodrugs of theophylline: topical delivery of theophylline. Int. J. Pharm. 167 (1998) 37-48
24. Malet-Martino M., Jolimaitre P., and Martino R. The prodrugs of 5-fluorouracil. Curr. Med. Chem. Anti-Cancer Agents 2 (2002) 267-310
25. McCarron P.A., Woolfson A.D., and Keating S.M. Response surface methodology as a predictive tool for determining the effects of preparation conditions on the physicochemical properties of poly(isobutylcyanoacrylate) nanoparticles. Int. J. Pharm. 193 (1999) 37-47
26. McCarron P.A., Woolfson A.D., and Keating S.M. Sustained release of 5-fluorouracil from polymeric nanoparticles. J. Pharm. Pharmacol. 52 (2000) 1451-1459
27. Mollgaard B., Hoelgaard A., and Bundgaard H. Pro-drugs as drug delivery systems. xxiii. Improved dermal delivery of 5-fluorouracil through human skin via n-acyloxymethyl pro-drug derivatives. Int. J. Pharm. 12 (1982) 153-162
28. Paul M., Fessi H., Laatiris A., Boulard Y., Durand R., Deniau M., and Astier A. Pentamidine-loaded poly(d,l-lactide) nanoparticles: physicochemical properties and stability work. Int. J. Pharm. 159 (1997) 223-232
29. Quintanar-Guerrero D., Allemann E., Doelker E., and Fessi H. A mechanistic study of the formation of polymer nanoparticles by the emulsification-diffusion technique. Colloid Polym. Sci. 275 (1997) 640-647
30. Rang H.P., Dale M.M., and Ritter J.M. Pharmacology (1995), Churchill-Livingstone, New York
31. Rautio J., Nevalainen T., Taipale H., Vepsalainen J., Gynther J., Laine K., and Jarvinen T. Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation. Eur. J. Pharm. Sci. 11 (2000) 157-163
32. Rimoli M.G., Avallone L., de Caprariis P., Galeone A., Forni F., and Vandelli M.A. Synthesis and characterisation of poly(-lactic acid)-idoxuridine conjugate. J. Control. Release 58 (1999) 61-68
33. Roberts W.J., and Sloan K.B. Correlation of aqueous and lipid solubilities with flux for prodrugs of 5-fluorouracil, theophylline, and 6-mercaptopurine: a Potts-Guy approach. J. Pharm Sci. 88 (1999) 515-522
34. Salomone B., Ponti R., Gasco M.R., Ugazio E., Quaglino P., Osella-Abate S., and Bernengo M.G. In vitro effects of cholesteryl butyrate solid lipid nanospheres as a butyric acid pro-drug on melanoma cells: evaluation of antiproliferative activity and apoptosis induction. Clin. Exp. Metastasis 18 (2001) 663-673
35. Schmoll H.J., Buchele T., Grothey A., and Dempke W. Where do we stand with 5-fluorouracil?. Semin. Oncol. 26 (1999) 589-605
36. Sloan K.B., Wasdo S., Ezike-Mkparu U., Murray T., Nickels D., Singh S., Shanks T., Tovar J., Ulmer K., and Waranis R. Topical delivery of 5-fluorouracil and 6-mercaptopurine by their alkylcarbonyloxymethyl prodrugs from water: vehicle effects on design of prodrugs. Pharm. Res. 20 (2003) 639-645
37. Taylor H.E., and Sloan K.B. 1-Alkylcarbonyloxymethyl prodrugs of 5-fluorouracil (5-fu): synthesis, physicochemical properties, and topical delivery of 5-fu. J. Pharm. Sci. 87 (1998) 15-20
38. Yuasa H., Matsuda K., Gu J., Suzuki E., Yokouchi I., and Watanabe J. Dose-dependent gastrointestinal absorption of 5-fluorouracil in rats in vivo. Biol. Pharm. Bull. 19 (1996) 1494-1498